Business
Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox
GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that Singapore’s Health Sciences Authority (HSA) has approved an expanded indication for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to include prevention of mpox disease in adults determined to be at high risk for mpox infection. The expanded indication in Singapore is supported by existing human safety data and data from a well-controlled animal study in which ACAM2000® vacci
About this update from Emergent Biosolutions Inc.
[{"type":"image","alt":"Emergent BioSolutions","displaySize":"","headline":null,"caption":"Emergent BioSolutions","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":36,"url":"https://media.zenfs.com/en/globenewswire.com/ac51a05701131dc10043a5f2860c099d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZhYU3Wj_ScFJfNSBcZGgMw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUw/https://media.zenfs.com/en/globenewswire.com/ac51a05701131dc10043a5f2860c099d","width":300,"height":36}},"lazy":false},{"type":"text","content":"GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that Singapore’s Health Sciences Authority (HSA) has approved an expanded indication for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to include prevention of mpox disease in adults determined to be at high risk for mpox infection.","length":350,"tagName":"p"},{"type":"text","content":"The expanded indication in Singapore is supported by existing human safety data and data from a well-controlled animal study in which ACAM2000® vaccine was shown to be effective in protecting against mpox virus exposure. This regulatory milestone expands the authorized use of ACAM2000® in Singapore to support public health preparedness and response efforts.","length":364,"tagName":"p"},{"type":"text","content":"“The Singapore HSA approval of ACAM2000® for immunization against mpox in high-risk individuals demonstrates the strength and breadth of Emergent’s medical countermeasures portfolio,” said Simon Lowry, chief medical officer of Emergent. “We are committed to working with international regulatory authorities as part of our broader vision to become the leader in delivering protective and life-saving solutions to communities around the world.”","length":443,"tagName":"p"},{"type":"text","content":"ACAM2000® is a single-dose vaccine administered percutaneously via a bifurcated needle dipped into the vaccine solution and used to prick the skin several times in the upper arm with a droplet of the vaccine. The vaccine was first approved by the HSA in 2009 for active immunization for the prevention of smallpox disease in individuals determined to be at high risk for smallpox infection. With this expanded indication, the vaccine is now also approved for active immunization for the prevention of mpox disease in adu...